Santhera Pharmaceuticals Holding AG’s obtaining a world-wide exclusive license for a product candidate for the treatment of cystic fibrosis from Polyphor

Santhera Pharmaceuticals Holding AG (SIX: SANN) announced that it had obtained a world-wide exclusive license from Swiss pharmaceutical company Polyphor AG to develop and commercialize a clinical stage product candidate for the treatment of cystic fibrosis and other pulmonary diseases.

Santhera paid the upfront payment of CHF 6.5 m in newly-issued shares representing 3.8% of Santhera’s share capital. The license also provides for cash milestone payments of up to CHF 121 m and other royalty and milestone payments.

Homburger has advised Santhera on the Swiss corporate and securities law aspects of the transaction with a team led by partner Dieter Gericke (picture) and comprised Daniel Häusermann (both Corporate | M&A).

Involved fees earner: Dieter Gericke – Homburger; Daniel Häusermann – Homburger;

Law Firms: Homburger;

Clients: Santhera Pharmaceuticals;